Related Experiment Videos
P450-expression in brain tumors
H Knüpfer1, M M Knüpfer, M Hotfilder
1University of Leipzig, Department of Clinical Pharmacology, Germany. popph@server3.medizin.uni-leipzig.de
Abstract:
Oxazaphosphorines are inactive anticancer prodrugs that are bioactivated by hepatic cytochrome P450. Besides hepatic metabolism, there is increasing interest in the possibility of intratumoral activation of oxazaphosphorines by P450. Therefore, we investigated the expression of P450 (CYP3A4, CYP3A5, CYP2C9) by RT-PCR in 10 different brain tumor samples. Because P450 may be downregulated by interleukin-1 (IL-1) and IL-6, the receptors for IL-1 and IL-6 were analyzed. None of the brain tumors was positive for CYP3A4 whereas CYP3A5 was detected in 3 out of 10 tumors (two meningeomas, one medulloblastoma grade IV). All five gliomas, an ependymoma, and a lymphoma-metastase gave no signal. CYP2C9 mRNA was present in every sample studied. All samples were positive for IL-1 and IL-6 receptors. In summary, we have demonstrated that tumors of the CNS express P450, indicating that activation of prodrugs like oxazaphosphorines may take place intratumorally. However, the most abundantly hepatically expressed CYP3A4 enzyme is absent in the brain tumor samples. The presence of the IL-1 and IL-6 receptors opens the possibility that the wellknown downregulating influence of these cytokines also takes place in brain tumors.
Insights
Brain tumors express cytochrome P450 enzymes, suggesting potential intratumoral activation of anticancer prodrugs like oxazaphosphorines. However, key enzymes like CYP3A4 are absent, and cytokine receptors are present.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Oxazaphosphorines are prodrugs requiring bioactivation by cytochrome P450 (P450) enzymes, primarily in the liver.
- Intratumoral activation of these prodrugs by P450 is an emerging area of interest for cancer therapy.
- Interleukin-1 (IL-1) and IL-6 are known to downregulate P450 expression, potentially affecting prodrug activation.
Purpose of the Study:
- To investigate the expression of specific P450 enzymes (CYP3A4, CYP3A5, CYP2C9) in human brain tumor samples.
- To analyze the presence of IL-1 and IL-6 receptors in these tumors, as these cytokines can influence P450 levels.
- To assess the potential for intratumoral activation of oxazaphosphorine prodrugs in brain tumors.
Main Methods:
- Reverse transcription polymerase chain reaction (RT-PCR) was used to detect mRNA expression of CYP3A4, CYP3A5, and CYP2C9.
- Ten different human brain tumor samples were analyzed.
- Expression of IL-1 and IL-6 receptors was also assessed in the tumor samples.
Main Results:
- CYP2C9 mRNA was detected in all brain tumor samples studied.
- CYP3A5 mRNA was found in 3 out of 10 tumors (two meningiomas, one medulloblastoma).
- CYP3A4 mRNA was not detected in any of the brain tumor samples. All samples expressed IL-1 and IL-6 receptors.
Conclusions:
- Brain tumors express certain P450 enzymes (CYP2C9 and, in some cases, CYP3A5), indicating a potential for intratumoral prodrug activation.
- The absence of CYP3A4, a major hepatic P450 enzyme, suggests differential activation pathways in brain tumors.
- The presence of IL-1 and IL-6 receptors suggests that cytokine-mediated downregulation of P450 may occur in brain tumors, impacting prodrug efficacy.